Bridging the UK, Poland and USA

OncoTherics Limited was established in the UK in 2009 by BioStatus Limited. BioStatus remains the company’s largest investor, with a cumulative investment of over £1 million. OncoTherics’ research and development has also been supported by other private investors and European regional grant funding. More details about BioStatus can be found at biostatus.com. OncoTherics Limited is a company registered in England and Wales, reg no: 06940617

OncoTherics Poland Sp. Zo.o. was formed in 2018 as a wholly owned Subsidiary of OncoTherics Limited to progress the commercialisation of the OncoTherics technology. On the 27th October 2021, the company transformed to a Spółka akcyjna (S.A.) company as part of a planned corporate development strategy. OncoTherics Poland S.A. is a company incorporated and registered in Poland with registered office at ul. Bobrzynskiego 14, 30-348 Krakow, Poland.

The company was successful in attracting European grant funding to progress its preclinical development programme.

Building our US presence

OncoTherics is establishing a US base and building the team and clinical collaborations needed to deliver its planned clinical trials.

The initial clinical priority is AQ4N in glioblastoma. This next stage builds on the company’s research and development foundations in the UK and Poland.

For further information please contact: enquiry@oncotherics.com